Effect of Epidermal Growth Factor Receptor Expression Level on Survival in Patients with Epithelial Ovarian Cancer
暂无分享,去创建一个
David L Rimm | M. Dimopoulos | D. Rimm | R. Camp | A. Psyrri | P. Weinberger | A. Bamias | Robert L Camp | Ziwei Yu | Diane Kowalski | Amanda Psyrri | Ziwei Yu | Mohamad Kassar | Aris Bamias | Paul M Weinberger | Sonia Markakis | Meletios A Dimopoulos | D. Kowalski | M. Kassar | Sonia Markakis
[1] Neal J Meropol,et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] K. Makino,et al. Nuclear localization of EGF receptor and its potential new role as a transcription factor , 2001, Nature Cell Biology.
[3] R. Bast,et al. CA125 Antigen Levels in Obstetric and Gynecologic Patients , 1984, Obstetrics and gynecology.
[4] T. Bauknecht,et al. Epidermal growth factor receptor and transforming growth factor alpha expression in human ovarian carcinomas. , 1992, European journal of cancer.
[5] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[6] W. Sauerbrei,et al. Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. , 1994, Journal of the National Cancer Institute.
[7] L. Schwartz,et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] E. Vokes,et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] G. Bauer,et al. Characterization of growth factors in human ovarian carcinomas. , 1986, Cancer research.
[10] J. Nesland,et al. Epidermal growth factor receptor expression has no independent prognostic significance in advanced ovarian cancer. , 1999, Anticancer research.
[11] David L Rimm,et al. Cyclin d1 is a valuable prognostic marker in oropharyngeal squamous cell carcinoma. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[12] D. Rimm,et al. X-Tile , 2004, Clinical Cancer Research.
[13] D L Rimm,et al. Tissue microarray: a new technology for amplification of tissue resources. , 2001, Cancer journal.
[14] D. Rimm,et al. Prognostic Significance of p 16 Protein Levels in Oropharyngeal Squamous Cell Cancer , 2004 .
[15] A. Schauer,et al. EGF-R and overexpression of the oncogene c-erbB-2 in ovarian cancer: immunohistochemical findings and prognostic value. , 1995, Journal of obstetrics and gynaecology.
[16] A new prognostic model comprising p53, EGFR, and tumor grade in early stage epithelial ovarian carcinoma and avoiding the problem of inaccurate surgical staging , 2004, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.
[17] N. Hacker,et al. Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells. , 2001, Journal of the National Cancer Institute.
[18] D. Rimm,et al. Automated subcellular localization and quantification of protein expression in tissue microarrays , 2002, Nature Medicine.
[19] M. Fukumoto,et al. Cyclin‐D1‐gene amplification is a more potent prognostic factor than its protein over‐expression in human head‐and‐neck squamous‐cell carcinoma , 1997, International journal of cancer.
[20] T. Bauknecht,et al. The expression of EGF receptors, EGF-like factors and c-myc in ovarian and cervical carcinomas and their potential clinical significance. , 1989, Anticancer research.
[21] G. Sherbet,et al. EPIDERMAL-GROWTH-FACTOR RECEPTORS AND OESTROGEN RECEPTORS IN HUMAN BREAST CANCER , 1985, The Lancet.
[22] T. Seidal,et al. A new prognostic model comprising p53, EGFR, and tumor grade in early stage epithelial ovarian carcinoma and avoiding the problem of inaccurate surgical staging , 2003, International Journal of Gynecologic Cancer.
[23] G. Carpenter. Nuclear localization and possible functions of receptor tyrosine kinases. , 2003, Current opinion in cell biology.
[24] M. Palmer,et al. WHO Handbook for Reporting Results of Cancer Treatment , 1982, British Journal of Cancer.
[25] D. Rimm,et al. Prognostic Significance of p16 Protein Levels in Oropharyngeal Squamous Cell Cancer , 2004, Clinical Cancer Research.
[26] G. Carpenter,et al. Receptors for epidermal growth factor and other polypeptide mitogens. , 1987, Annual review of biochemistry.
[27] Armando Santoro,et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. , 2004, The New England journal of medicine.
[28] T. Bauknecht,et al. Expression analysis of EGF-R and TGFa in human ovarian carcinomas. , 1991, Anticancer research.
[29] A. Jakobsen,et al. Prognostic significance of p53, Her‐2, and EGFR overexpression in borderline and epithelial ovarian cancer , 2004, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.
[30] R. Bast,et al. Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer. , 1991, American journal of obstetrics and gynecology.
[31] A. Jemal,et al. Cancer Statistics, 2004 , 2004, CA: a cancer journal for clinicians.
[32] Silvia Benvenuti,et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. , 2005, The Lancet. Oncology.
[33] R. D. Hunter,et al. WHO Handbook for Reporting Results of Cancer Treatment , 1980 .
[34] Bruce G. Haffty,et al. β-Catenin Functions Mainly as an Adhesion Molecule in Patients with Squamous Cell Cancer of the Head and Neck , 2005, Clinical Cancer Research.
[35] G. Rustin,et al. Role of tumour markers in monitoring epithelial ovarian cancer , 2000, British Journal of Cancer.